Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome

Blood

Volumn 120, Issue 17, 2012, Pages 3419-3424

  Komrokji, Rami S ^a   Lancet, Jeffrey E ^a   Swern, Arlene S ^b   Chen, Nianhang ^b   Paleveda, Jennifer ^a   Lush, Richard ^a   Saba, Hussain I ^a   List, Alan F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ERYTHROPOIETIN; LENALIDOMIDE; RECOMBINANT ERYTHROPOIETIN;

5Q- SYNDROME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CYTOGENETICS; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; ERYTHROCYTE TRANSFUSION; ERYTHROID CELL; FEMALE; HUMAN; LOW RISK POPULATION; MALE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; STEADY STATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

EID: 84867612592     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-415661     Document Type: Article

References (13)

1. Komrokji RS, Sekeres MA, List AF. Management of lower-risk myelodysplastic syndromes: the art and evidence. Curr Hematol Malig Rep. 2011; 6(2):145-153.
2. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al. Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6): 1037-1046. (Pubitemid 36411563)
3. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14): 1456-1465. (Pubitemid 44511560)
4. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111(1):86-93.
5. Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematol Oncol Clin North Am. 2010;24(2):377-388.
6. Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 2008;5(2):e35.
7. Komrokji R, Giagounidis A, List A. Lenalidomide therapy in MDS. In: Steensma DP, ed. Myelodysplastic Syndromes: Pathobiology and Clinical Management. 2nd Ed. London, United Kingdom: Informa Health Care; 2008:457-483.
8. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549-557. (Pubitemid 40204668)
9. List AF. Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes. Cancer Control. 2006;13(Suppl):12-16. (Pubitemid 46148105)
10. Greenberg P, Cox C, Lebeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6): 2079-2088. (Pubitemid 27132124)
11. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(12):3671-3674.
12. Celgene Corporation. Revlimide (lenalidomide) 5 mg, 10 mg, 15 mg and 25 mg capsules prescribing information USA. http://www.revlimid. com/pdf/REVLIMID-PI.pdf. Accessed December 1, 2008.
13. List AF, Estes M, Williams A, et al. Lenalidomide (CC-5013; Revlimid(R)) promotes erythropoiesis in myelodysplastic syndromes (MDS) by CD45 protein tyrosine phosphatase (PTP) inhibition [abstract]. Blood (ASH Annual Meeting Abstracts). 2006;108(11):1360.